Lumos Pharma, Inc. (LUMO)
| Previous close | 9.30 |
| Open | 9.33 |
| Bid | 9.24 x 800 |
| Ask | 9.45 x 1000 |
| Day's range | 9.25 - 9.45 |
| 52-week range | 7.23 - 36.72 |
| Volume | 1,951 |
| Avg. volume | 62,612 |
| Market cap | 77.452M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.16 |
| Earnings date | 08 Nov 2021 - 12 Nov 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 27.00 |
- GlobeNewswire
Lumos Pharma to Participate in September Investor Conferences
AUSTIN, Texas, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the H.C. Wainwright 23rd Annual Global Investment Conference and the Cantor Virtual Global Healthcare Conference in September. Event:H.C. Wainwright 23rd Annual Global Investor Conference – September 13-15Presentation:Pre-recorded presentation available beginning September 13 at 7:0
- Simply Wall St.
Great news for Lumos Pharma, Inc. (NASDAQ:LUMO): Insiders acquired stock in large numbers last year
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...
- GlobeNewswire
Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
• Lumos Pharma strengthens leadership team with promotion of John McKew, PhD to President, and addition of David B. Karpf, MD as Chief Medical Officer and Mark Bach, MD, PhD to Advisory Board • Screening and enrollment of OraGrowtH210 and OraGrowtH212 Trials progress AUSTIN, Texas, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results for the second quarter ending June
